Dare Bioscience, Inc. annual report, FY2019

Dare Bioscience, Inc. — FY2019 Form 10-K

Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter filing; the filing compares full-year 2019 with full-year 2018. Dare is a clinical-stage women’s-health biopharmaceutical company with no approved products or product revenue.

Business context and pipeline

The company’s strategy is to license or acquire women’s-health candidates, advance them through clinical development, and partner with companies that have commercial capabilities. Its leading programs are DARE-BV1 for bacterial vaginosis, Ovaprene for hormone-free contraception, and Sildenafil Cream 3.6% for female sexual arousal disorder. DARE-HRT1, DARE-VVA1 and DARE-FRT1 were described as Phase 1-ready or in preparation. Dare also acquired Microchips Biotech in November 2019, adding a preclinical implantable drug-delivery contraceptive program.

Financial and liquidity highlights

MetricFY2019 / Dec. 31, 2019FY2018 / Dec. 31, 2018
Revenue$0$0
Research and development expense$8.55 million$6.41 million
General and administrative expense$5.27 million$4.66 million
Total operating expenses$14.34 million$16.88 million
Net loss$14.26 million$16.74 million
Net loss per share, basic and diluted$0.97$1.57
Cash used in operating activities$13.32 million$10.27 million
Cash and cash equivalents$4.78 million$6.81 million
Working capital$0.8 millionNot stated here
Total liabilities$7.00 million$1.10 million
Stockholders’ equity$0.44 million$6.73 million

Margins are not meaningful because the company reported no revenue. The filing reports no conventional borrowings in the financial statements; liabilities included lease obligations and $1.0 million of noncurrent contingent consideration, as well as operating payables and deferred grant funding. No off-balance-sheet arrangements were reported.

Changes versus FY2018

  • Net loss narrowed by about $2.47 million, mainly because FY2018 included a $5.19 million goodwill impairment. R&D expense rose about $2.13 million as development activity expanded; G&A increased about $0.61 million.
  • Operating cash use increased about $3.05 million, while year-end cash fell about $2.03 million. The company funded operations partly through a 2019 equity offering and cash acquired with Microchips.
  • Common shares outstanding rose from 11.42 million to 19.68 million during 2019, reflecting the public offering and Microchips acquisition. A down-round feature on warrants triggered a $0.79 million deemed dividend and reduced the warrants’ exercise price to $0.98.

Outlook, commentary and key risks

  • Going concern: Management and the independent auditor cited substantial doubt about the company’s ability to continue as a going concern. Management stated that cash was insufficient for the next 12 months from issuance of the financial statements without additional capital or significant operating reductions. The statements were prepared on a going-concern basis without adjustments for this uncertainty.
  • Funding and spending: Management expected R&D expenses to increase significantly in 2020, with planned studies for DARE-BV1, Ovaprene, Sildenafil Cream and DARE-HRT1. The filing does not provide a clear consolidated cash-runway estimate beyond the stated insufficiency for the following 12 months.
  • Program targets: The company expected to initiate a Phase 3 DARE-BV1 study in the second half of 2020 and, if successful with required nonclinical work, to be positioned to file an NDA in early 2021. It estimated approximately $10 million in aggregate DARE-BV1 study, nonclinical, manufacturing and filing costs. It planned to initiate Ovaprene’s pivotal study in the second half of 2020, subject to FDA review of an IDE; a Phase 2b Sildenafil Cream study and Phase 1 DARE-HRT1 study were also planned for 2020. These are forward-looking expectations, not commitments.
  • Ovaprene/Bayer: Under a January 2020 agreement, Bayer paid $1 million upfront and could elect, in its sole discretion, to pay an additional $20 million after reviewing pivotal-trial results to activate the U.S. license. Bayer may terminate on 90 days’ notice. Potential future milestones and royalties depend on development and sales; they are not guaranteed funding.
  • COVID-19: The company warned that the pandemic could delay trials, enrollment, regulatory review and supplies, increase costs, and impair access to capital. The scale of impact was uncertain at filing.
  • Development and commercial risks: Candidates remain unapproved and clinical outcomes are uncertain. The company depends on third-party manufacturers, vendors and licensors, including some single-source suppliers; it has no internal sales infrastructure. Other risks include competition, reimbursement and market acceptance, intellectual-property protection, license obligations, dilution from future financing, and Nasdaq listing compliance.
  • Clinical data: The Ovaprene postcoital study met its reported primary endpoint, but this is a surrogate measure and does not establish pregnancy-prevention effectiveness. DARE-BV1’s encouraging proof-of-concept findings came from a small study and may not be replicated in Phase 3.

Most important facts for investors to verify

  • Current unrestricted cash, operating burn, financing needs and whether the company has secured funding sufficient to execute planned trials.
  • Actual trial start dates, enrollment progress, final results and FDA feedback for DARE-BV1, Ovaprene and Sildenafil Cream.
  • Whether Bayer elects to pay the additional $20 million, and the terms and status of the Ovaprene license.
  • Changes in share count, warrant exercises, dilution and the company’s ability to maintain Nasdaq listing requirements.
  • Any COVID-related supply, trial, regulatory or cost delays, and any changes to the auditor’s or management’s going-concern assessment.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.